Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2021 |
| Outros Autores: | , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/50655 |
Resumo: | Dados da pesquisa estão no anexo do artigo. |
| id |
CRUZ_26b83d0677bb2a31cb34705b6b4ae8ec |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/50655 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Silva, Thiago CerqueiraAndrews, Jason R.Boaventura, Viviane S.Ranzani, Otavio T.Oliveira, Vinicius de AraújoPaixão, Enny S.Bertoldo Júnior, JuracyMachado, Tales MotaHitchings, Matt D.T.Dorion, MuriloLind, Margaret L.Penna, Gerson OliveiraCummings, Derek A.T.Dean, Natalie E.Werneck, Guilherme LoureiroBarreto, Maurício LimaKo, Albert IcksangCroda, JulioBarral Netto, Manoel2022-01-06T01:29:04Z2022-01-06T01:29:04Z2021CERQUEIRA-SILVA, Thiago et al. Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil. The BMJ, p. 1-30, 27 Dec. 2021.https://www.arca.fiocruz.br/handle/icict/5065510.1101/2021.12.21.21268058Dados da pesquisa estão no anexo do artigo.Todos os dados foram pseudo-anônimos com um identificador único comum fornecido pelo Ministério da Saúde do Brasil. O protocolo de pesquisa foi aprovado pela Comissão Nacional de Ética em Pesquisa (CONEP) (número de aprovação 4.921.308).Conselho Nacional de Pesquisa, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Fundação Oswaldo Cruz, JBS SA, Instituto de Salud Carlos III, Ministério da Ciência e Inovação da Espanha, Generalitat de Catalunya.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Universidade Federal da Bahia. Salvador, BA, Brasil.Stanford University. Division of Infectious Diseases and Geographic Medicine. Stanford, CA, United States.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Universidade Federal da Bahia. Salvador, BA, Brasil.ISGlobal. Barcelona Institute for Global Health. Barcelona, Spain / Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Heart Institute. Pulmonary Division. São Paulo, SP, Brazil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Integração de Dados e Conhecimentos para Saúde. Salvador, BA, Brasil.London School of Hygiene and Tropical Medicine. London, United Kingdom.Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Integração de Dados e Conhecimentos para Saúde. Salvador, BA, Brasil.Universidade Federal de Ouro Preto. Ouro Preto, MG, Brasil.University of Florida. College of Public Health & Health Professions. Department of Biostatistics. Gainesville, FL, United States.Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Heaven, CT, United States.Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Heaven, CT, United States.Universidade de Brasília. Núcleo de Medicina Tropical. Brasília, DF, Brasil / Fundação Oswaldo Cruz. Escola de Governo Fiocruz Brasília. Brasília, DF, Brasil.University of Florida. Department of Biology. Gainesville, FL, United States / University of Florida. Emerging Pathogens Institute. Gainesville, FL, United States.Emory University. Rollins School of Public Health. Department of Biostatistics & Bioinformatics. Atlanta, GA, United States.Universidade do Estado do Rio de Janeiro. Rio de Janeiro, RJ, Brazil.London School of Hygiene and Tropical Medicine. London, United Kingdom.Stanford University. Division of Infectious Diseases and Geographic Medicine. Stanford, CA, United States / Fundação Oswaldo Cruz. Centro de Integração de Dados e Conhecimentos para Saúde. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Heaven, CT, United States.Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Heaven, CT, United States / Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brasil / Fundação Oswaldo Cruz. Fiocruz Mato Grosso do Sul. Campo Grande, MS, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Integração de Dados e Conhecimentos para Saúde. Salvador, BA, Brasil.Background: COVID-19 vaccines have proven highly effective among SARS-CoV-2 naive individuals, but their effectiveness in preventing symptomatic infection and severe outcomes among individuals with prior infection is less clear. Methods: Utilizing national COVID-19 notification, hospitalization, and vaccination datasets from Brazil, we performed a case-control study using a test-negative design to assess the effectiveness of four vaccines (CoronaVac, ChAdOx1, Ad26.COV2.S and BNT162b2) among individuals with laboratory-confirmed prior SARS-CoV-2 infection. We matched RTPCR positive, symptomatic COVID-19 cases with RT-PCR-negative controls presenting with symptomatic illnesses, restricting both groups to tests performed at least 90 days after an initial infection. We used multivariable conditional logistic regression to compare the odds of test positivity, and the odds of hospitalization or death due to COVID-19, according to vaccination status and time since first or second dose of vaccines. Findings: Among individuals with prior SARS-CoV-2 infection, vaccine effectiveness against symptomatic infection ≥ 14 days from vaccine series completion was 39.4% (95% CI 36.1-42.6) for CoronaVac, 56.0% (95% CI 51.4-60.2) for ChAdOx1, 44.0% (95% CI 31.5- 54.2) for Ad26.COV2.S, and 64.8% (95% CI 54.9-72.4) for BNT162b2. For the two-dose vaccine series (CoronaVac, ChAdOx1, and BNT162b2), effectiveness against symptomatic infection was significantly greater after the second dose compared with the first dose. Effectiveness against hospitalization or death ≥ 14 days from vaccine series completion was 81.3% (95% CI 75.3-85.8) for CoronaVac, 89.9% (95% CI 83.5-93.8) for ChAdOx1, 57.7% (95% CI -2.6-82.5) for Ad26.COV2.S, and 89.7% (95% CI 54.3-97.7) for BNT162b2. Interpretation. All four vaccines conferred additional protection against symptomatic infections and severe outcomes among individuals with previous SARS-CoV-2 infection. Provision of a full vaccine series to individuals following recovery from COVID-19 may reduce morbidity and mortality.engYale UniversityCoronavírusCOVID-19CoronaVacEstudos de casos e controlesControle de doenças transmissíveisCOVID-19CoronaVacChAdOx1BNT162b2 and Ad26.COV2.STest-negative studyCase-control studyPrevious infectionsEffectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazilinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleNão publicado.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83074https://www.arca.fiocruz.br/bitstream/icict/50655/1/license.txtd3e717dbb24bfc607ede047f44d29a0eMD51ORIGINALCerqueira-Silva_Thiago_etal_Fiocruz_BSB_COVID-19_2021.pdfCerqueira-Silva_Thiago_etal_Fiocruz_BSB_COVID-19_2021.pdfapplication/pdf1583622https://www.arca.fiocruz.br/bitstream/icict/50655/2/Cerqueira-Silva_Thiago_etal_Fiocruz_BSB_COVID-19_2021.pdf498aafeaabf3f288cff82e6f0d43f299MD52icict/506552022-07-18 16:00:44.293oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-07-18T19:00:44Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil |
| title |
Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil |
| spellingShingle |
Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil Silva, Thiago Cerqueira Coronavírus COVID-19 CoronaVac Estudos de casos e controles Controle de doenças transmissíveis COVID-19 CoronaVac ChAdOx1 BNT162b2 and Ad26.COV2.S Test-negative study Case-control study Previous infections |
| title_short |
Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil |
| title_full |
Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil |
| title_fullStr |
Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil |
| title_full_unstemmed |
Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil |
| title_sort |
Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil |
| author |
Silva, Thiago Cerqueira |
| author_facet |
Silva, Thiago Cerqueira Andrews, Jason R. Boaventura, Viviane S. Ranzani, Otavio T. Oliveira, Vinicius de Araújo Paixão, Enny S. Bertoldo Júnior, Juracy Machado, Tales Mota Hitchings, Matt D.T. Dorion, Murilo Lind, Margaret L. Penna, Gerson Oliveira Cummings, Derek A.T. Dean, Natalie E. Werneck, Guilherme Loureiro Barreto, Maurício Lima Ko, Albert Icksang Croda, Julio Barral Netto, Manoel |
| author_role |
author |
| author2 |
Andrews, Jason R. Boaventura, Viviane S. Ranzani, Otavio T. Oliveira, Vinicius de Araújo Paixão, Enny S. Bertoldo Júnior, Juracy Machado, Tales Mota Hitchings, Matt D.T. Dorion, Murilo Lind, Margaret L. Penna, Gerson Oliveira Cummings, Derek A.T. Dean, Natalie E. Werneck, Guilherme Loureiro Barreto, Maurício Lima Ko, Albert Icksang Croda, Julio Barral Netto, Manoel |
| author2_role |
author author author author author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Silva, Thiago Cerqueira Andrews, Jason R. Boaventura, Viviane S. Ranzani, Otavio T. Oliveira, Vinicius de Araújo Paixão, Enny S. Bertoldo Júnior, Juracy Machado, Tales Mota Hitchings, Matt D.T. Dorion, Murilo Lind, Margaret L. Penna, Gerson Oliveira Cummings, Derek A.T. Dean, Natalie E. Werneck, Guilherme Loureiro Barreto, Maurício Lima Ko, Albert Icksang Croda, Julio Barral Netto, Manoel |
| dc.subject.other.pt_BR.fl_str_mv |
Coronavírus COVID-19 CoronaVac Estudos de casos e controles Controle de doenças transmissíveis |
| topic |
Coronavírus COVID-19 CoronaVac Estudos de casos e controles Controle de doenças transmissíveis COVID-19 CoronaVac ChAdOx1 BNT162b2 and Ad26.COV2.S Test-negative study Case-control study Previous infections |
| dc.subject.en.pt_BR.fl_str_mv |
COVID-19 CoronaVac ChAdOx1 BNT162b2 and Ad26.COV2.S Test-negative study Case-control study Previous infections |
| description |
Dados da pesquisa estão no anexo do artigo. |
| publishDate |
2021 |
| dc.date.issued.fl_str_mv |
2021 |
| dc.date.accessioned.fl_str_mv |
2022-01-06T01:29:04Z |
| dc.date.available.fl_str_mv |
2022-01-06T01:29:04Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
CERQUEIRA-SILVA, Thiago et al. Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil. The BMJ, p. 1-30, 27 Dec. 2021. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/50655 |
| dc.identifier.doi.none.fl_str_mv |
10.1101/2021.12.21.21268058 |
| identifier_str_mv |
CERQUEIRA-SILVA, Thiago et al. Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil. The BMJ, p. 1-30, 27 Dec. 2021. 10.1101/2021.12.21.21268058 |
| url |
https://www.arca.fiocruz.br/handle/icict/50655 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Yale University |
| publisher.none.fl_str_mv |
Yale University |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/50655/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/50655/2/Cerqueira-Silva_Thiago_etal_Fiocruz_BSB_COVID-19_2021.pdf |
| bitstream.checksum.fl_str_mv |
d3e717dbb24bfc607ede047f44d29a0e 498aafeaabf3f288cff82e6f0d43f299 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813009049221857280 |